multiple sclerosisImmunic CEO: “We want to understand MS patients better than anyone”Immunic is preparing to transition from a late-stage development biotechnology company into a fully integrated commercial organization focused on multiple sclerosis (MS). At the center of its strategy … more ➔
licensingAstraZeneca boards the PD-1/VEGF ship with $2B Summit investmentAstraZeneca has agreed to invest $2 billion (€1.8 billion) in Summit Therapeutics and test its cancer drug ivonescimab alongside the British pharma’s antibody-drug conjugates. more ➔
clinical datauniQure falls as Huntington’s gene therapy shows mixed resultsuniQure’s shares fell about 40% in early trading on September 29 after its Huntington’s gene therapy missed statistical significance on the main disease progression measure after four years. The … more ➔
fundraisingAnaCardio raises €62.5M to test heart failure drugSwedish biotech AnaCardio has raised €62.5 million to take its oral heart failure drug AC01 through Phase 2b, testing whether early improvements in pumping function hold up in a larger patient pop … more ➔
startupsAptadir secures €40M for gene-reactivating RNA drugsAptadir Therapeutics has raised €40 million in seed funding to advance an RNA therapy designed to reactivate the gene silenced in Fragile X syndrome. more ➔
fundingBreye raises €67.5M for diabetic eye disease trial with Novo Holdings backingDanish biotech Breye Therapeutics has raised €67.5 million to advance an oral eye disease drug candidate into a Phase 2 clinical trial. more ➔
anti-obesityNovo pays up to $2.6B for Hengrui’s once-weekly obesity pill candidateNovo Nordisk will pay China’s Jiangsu Hengrui Pharmaceuticals $300 million (€264 million) upfront, in a deal worth up to $2.6 billion (€2.3 billion), for rights outside Greater China to HRS-1596, … more ➔
WatchlistSix Spanish biotech startups to watch in 2026The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: Spain counted 1,119 dedicated biotech companies in 2025, up 10.4% year on year, … more ➔
RegulatoryFDA keeps Newron’s evenamide trial on hold in U.S.Newron Pharmaceuticals will expand its Phase 3 evenamide trial outside the U.S. after the FDA decided to maintain a hold on enrollment at American sites. more ➔
licensingAddex regains rights to addiction drug candidate from IndiviorSwiss biotech Addex Therapeutics has regained global rights to a GABA-B drug portfolio from Indivior, including a candidate for substance use disorders that has completed studies needed before a Phase … more ➔
